|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 5,482,963
United States Patent 5,482,963, granted on January 9, 1996, to Baxter International Inc., details a method for treating or preventing immunodeficiency disorders. The patent covers the use of specific immunoglobulin G (IgG) compositions.
What is the Core Invention Claimed in Patent 5,482,963?
Patent 5,482,963 claims a method for treating or preventing immunodeficiency disorders through the administration of a specific composition of human immunoglobulin G (IgG). The claims are focused on the therapeutic application of IgG, emphasizing its role in bolstering the immune system.
- Claim 1: This is the primary method claim, specifying the administration of a human IgG composition to a subject in need of such treatment. The composition is defined by its high purity and specific concentration range. The disorder targeted is an immunodeficiency disorder.
- Claim 2: This claim builds upon Claim 1 by further defining the immunodeficiency disorder as one selected from a list including primary immunodeficiency, acquired immunodeficiency syndrome (AIDS), and AIDS-related complex (ARC).
- Claim 3: This claim specifies the route of administration as intravenous.
- Claim 4: This claim quantifies the dosage range for the IgG composition, stating it to be from 200 to 600 mg/kg of body weight.
- Claim 5: This claim defines the IgG composition further, specifying it to be at least 96% IgG.
- Claim 6: This claim specifies the purity of the IgG composition, stating it to be substantially free of other plasma proteins.
What are the Specific Embodiments and Limitations of the Patented Technology?
The patent describes specific characteristics of the IgG composition and its intended use. These details are crucial for understanding the scope of protection.
IgG Composition Specifications:
- Purity: The IgG composition is characterized by a high degree of purity, specifically at least 96% IgG. This is a key differentiator from less refined plasma-derived products.
- Concentration: The patent implies a standardized concentration suitable for therapeutic administration, with a defined dosage range.
- Free of Other Proteins: A significant aspect of the composition is that it is substantially free of other plasma proteins. This suggests a purification process designed to isolate IgG, potentially reducing the risk of adverse reactions associated with other blood components.
- Source: The IgG is derived from human plasma.
Therapeutic Applications:
- Primary Immunodeficiency: This category includes genetic disorders where the immune system is weakened from birth.
- Acquired Immunodeficiency Syndrome (AIDS): This is a chronic condition that damages the immune system, caused by the human immunodeficiency virus (HIV).
- AIDS-Related Complex (ARC): This term, historically used for symptomatic HIV infection not yet meeting the criteria for AIDS, is also included.
Administration Details:
- Intravenous Administration: The patent specifically claims the intravenous route for administering the IgG composition. This method ensures rapid and direct delivery into the bloodstream.
- Dosage Range: A therapeutic dosage range of 200 to 600 mg/kg of body weight is stipulated. This provides a quantifiable parameter for the patented method.
What is the Technical Background and Prior Art Referenced in the Patent?
The patent acknowledges existing knowledge and technologies related to immunoglobulin therapy. The prior art addressed includes existing methods for preparing and using IgG for therapeutic purposes, particularly for treating immunodeficiency.
- Existing Immunoglobulin Therapy: The patent recognizes that immunoglobulins have been used therapeutically for some time. The innovation lies in the specific composition and claimed method of treatment.
- Plasma Fractionation: The development of techniques for fractionating human plasma to isolate specific proteins, including IgG, is a foundational element addressed.
- Treatment of Immunodeficiencies: The general understanding of immunodeficiency disorders and the rationale for immune support are implicit in the background.
The patent aims to differentiate its claimed method by focusing on a more purified IgG preparation and specific therapeutic indications and dosages, suggesting an improvement over prior art in terms of efficacy or safety.
What is the Patent Landscape Surrounding US Patent 5,482,963?
The patent landscape for immunoglobulin therapy is broad and has evolved significantly since 1996. US Patent 5,482,963 is situated within a field that includes numerous patents covering:
- Methods of Manufacturing and Purification of Immunoglobulins: This includes patents on chromatographic separation techniques, viral inactivation methods, and formulation processes to ensure stability and efficacy.
- Specific Formulations of IgG: Patents may claim novel formulations that enhance bioavailability, reduce viscosity, or improve patient tolerance. This can include different excipients, stabilizers, or concentrations.
- Therapeutic Uses of IgG: Beyond general immunodeficiency, patents exist for specific applications of IgG in treating autoimmune diseases, inflammatory conditions, and neurological disorders.
- Novel Immunoglobulin Variants or Derivatives: Research has led to patents on engineered IgG molecules with altered effector functions or half-lives.
Companies active in the immunoglobulin market, such as Takeda (following its acquisition of Shire), CSL Behring, Grifols, and Octapharma, hold extensive patent portfolios in this area. The expiry of foundational patents, like US 5,482,963, often opens avenues for generic or biosimilar competition, provided that subsequent patents covering manufacturing processes, formulations, or specific indications are also expired or circumvented.
The expiration of US 5,482,963 on January 9, 2013 (20 years from the filing date of December 26, 1991, minus any patent term extensions) means that the core method claims are no longer enforceable. However, the commercial viability of a drug based on this patent would also depend on the patent status of its specific formulation, manufacturing process, and any subsequent indications or dosages approved by regulatory bodies.
What are the Key Implications of this Patent for R&D and Investment?
The analysis of US Patent 5,482,963 offers several key implications for R&D and investment in the pharmaceutical sector.
R&D Implications:
- Foundation for IgG Therapy: This patent represents an early step in the development of standardized, purified IgG therapies for immunodeficiency. Subsequent R&D has focused on optimizing manufacturing, improving patient convenience (e.g., subcutaneous administration), and expanding therapeutic indications.
- Focus on Purity and Formulation: The emphasis on high purity and freedom from other plasma proteins in the patent highlights the direction of R&D towards safer and more effective IgG products. This continues to be a critical area, with ongoing research into novel purification methods and analytical techniques.
- Targeting Specific Immunodeficiencies: While the patent broadly covers immunodeficiency disorders, further R&D has refined the use of IgG for specific conditions within primary immunodeficiencies and also in secondary immunodeficiencies.
- Route of Administration: The patent's focus on intravenous administration has spurred further innovation in developing subcutaneous IgG formulations to improve patient compliance and reduce infusion-related adverse events.
Investment Implications:
- Market Entry for Generic/Biosimilar Products: The expiration of the primary claims of US Patent 5,482,963 has removed a barrier for companies seeking to develop and market generic or biosimilar IgG products for the specific method claims. However, market entry is contingent on the patent status of existing branded products and their associated technologies.
- Valuation of Established IgG Therapies: For investors, understanding the patent expiry of foundational patents is crucial for valuing established IgG therapies. The presence of later-expiring patents on formulation, manufacturing, or specific indications can extend market exclusivity for branded products.
- Pipeline Analysis: Investors analyzing companies in the immunoglobulin space must scrutinize their patent portfolios, looking for patents that protect novel formulations, manufacturing processes, or new therapeutic uses that extend beyond the expiration of older, broader patents.
- Regulatory Pathway: While patent protection is critical, regulatory approval for manufacturing and marketing is equally important. Investors should consider the time and cost associated with navigating these pathways, especially for biosimilars.
The expiration of US 5,482,963 signifies the maturation of a segment of the immunoglobulin market. Companies seeking to compete will need to differentiate through innovation in formulation, manufacturing efficiency, or novel therapeutic applications that may be protected by later-expiring patents.
Key Takeaways
- US Patent 5,482,963, granted to Baxter International Inc., claims a method for treating immunodeficiency disorders using a purified human IgG composition administered intravenously at a dosage of 200-600 mg/kg.
- The core innovation lies in the specific composition of IgG (at least 96% pure, substantially free of other plasma proteins) and its application to primary immunodeficiency, AIDS, and ARC.
- The patent expired on January 9, 2013, removing its claims from enforceability.
- This expiration has implications for generic and biosimilar market entry, though competition is also governed by later-expiring patents on formulations, manufacturing processes, and specific therapeutic indications.
- R&D in this field has progressed from basic IgG therapy to sophisticated formulations and expanded therapeutic uses, while investment analysis must consider the interplay of patent expiry, regulatory hurdles, and ongoing innovation.
Frequently Asked Questions
What is the current patent status of US Patent 5,482,963?
US Patent 5,482,963 expired on January 9, 2013. Its 20-year term, calculated from its filing date of December 26, 1991, had concluded.
Can companies now freely manufacture and sell IgG products based on the claims of US Patent 5,482,963?
While the claims of US Patent 5,482,963 are no longer enforceable, other patents covering specific manufacturing processes, formulations, or therapeutic indications of IgG products may still be in force. Therefore, freedom to operate depends on the patent landscape beyond this specific patent.
What specific immunodeficiency disorders were covered by this patent?
The patent covers a range of immunodeficiency disorders, specifically including primary immunodeficiency, acquired immunodeficiency syndrome (AIDS), and AIDS-related complex (ARC).
Did the patent claim the IgG product itself, or the method of using it?
US Patent 5,482,963 primarily claims the method of treating or preventing immunodeficiency disorders. It does not claim the IgG product in isolation but rather its specific application.
What was the significance of the purity and composition requirements in the patent?
The patent's emphasis on a highly purified IgG composition (at least 96% IgG and substantially free of other plasma proteins) aimed to define a superior therapeutic product compared to less refined plasma derivatives, potentially offering improved efficacy or safety profiles.
Citations
[1] Baxter International Inc. (1996). US Patent 5,482,963: Method of treating immunodeficiency disorders. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
